RELATED CONTENT
NEWS
- Focus on Almirall: partnering, new products and mature markets are key targets
- In bone drug quandary, FDA seeks panel's advice on safety, 'drug holidays'
- Panel urges FDA to reject Novartis gouty arthritis drug on safety concerns
- Industry views sought on EMA genomic biomarker consultation in drug development

